Breaking News

WuXi Biologics, Bioasis in Strategic Dev./Mfg. Alliance

WuXi Biologics to support analytical development, formulation and IND-enabling in vivo studies for xB3-001

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics and Bioasis Technologies, Inc. have entered an initial strategic collaboration for the development and manufacture of xB3-001, Bioasis’ lead biologic candidate to treat brain cancer.    Bioasis is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, including brain cancers and neurodegenerative diseases.   Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a glo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters